Association ofSOD3 promoter DNA methylation with its down-regulation in breast carcinomas

References

• National Cancer Institute. Bethesda M. seer cancer statistics review. 2019 April; Available from: https://seer.cancer.gov/csr/1975_2016/.
   Google Scholar
• Prat A, Pineda E, Adamo B, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015;24(Suppl 2):S26–35.
   PubMedGoogle Scholar
• Smid M, Wang Y, Zhang Y, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008;68(9):3108–3114.
   PubMed Web of Science ®Google Scholar
• Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752.
   PubMed Web of Science ®Google Scholar
• Furrukh M, Qureshi A. Treatment of breast cancer; review and updates. J Ayub Med Coll Abbottabad. 2018;30(2):264–274.
   PubMedGoogle Scholar
• Faraoni I, Graziani G. Role of BRCA mutations in cancer treatment with poly(ADP-ribose) polymerase (PARP) inhibitors. Cancers (Basel). 2018;10(12):487.
   PubMed Web of Science ®Google Scholar
• Teoh-Fitzgerald ML, Fitzgerald MP, Zhong W, et al. Epigenetic reprogramming governs EcSOD expression during human mammary epithelial cell differentiation, tumorigenesis and metastasis. Oncogene. 2014;33(3):358–368.
   PubMed Web of Science ®Google Scholar
• Griess B, Tom E, Domann F, et al. Extracellular superoxide dismutase and its role in cancer. Free Radic Biol Med. 2017;112:464–479.
   PubMed Web of Science ®Google Scholar
• Sies H. Hydrogen peroxide as a central redox signaling molecule in physiological oxidative stress: oxidative eustress. Redox Biol. 2017;11:613–619.
   PubMed Web of Science ®Google Scholar
• Perry JJ, Shin DS, Getzoff ED, et al. The structural biochemistry of the superoxide dismutases. Biochim Biophys Acta. 2010;1804(2):245–262.
   PubMed Web of Science ®Google Scholar
• Marklund SL. Extracellular superoxide dismutase in human tissues and human cell lines. J Clin Invest. 1984;74(4):1398–1403.
   PubMed Web of Science ®Google Scholar
• Marklund SL, Holme E, Hellner L. Superoxide dismutase in extracellular fluids. Clin Chim Acta. 1982;126(1):41–51.
   PubMed Web of Science ®Google Scholar
• Hicks CL. Occurrence and consequence of superoxide dismutase in milk products: a review. J Dairy Sci. 1980;63(7):1199–1204.
   PubMed Web of Science ®Google Scholar
• Golden BO, Griess B, Mir S, et al. Extracellular superoxide dismutase inhibits hepatocyte growth factor-mediated breast cancer-fibroblast interactions. Oncotarget. 2017;8(64):107390–107408.
   PubMedGoogle Scholar
• O’Leary BR, Fath MA, Bellizzi AM, et al. Loss of SOD3 (EcSOD) expression promotes an aggressive phenotype in human pancreatic ductal adenocarcinoma. Clin Cancer Res. 2015;21(7):1741–1751.
   PubMed Web of Science ®Google Scholar
• Jones PA. DNA methylation and cancer. Oncogene. 2002;21(35):5358–5360.
   PubMedGoogle Scholar
• Ho-Yen CM, Jones JL, Kermorgant S. The clinical and functional significance of c-Met in breast cancer: a review. Breast Cancer Res. 2015;17:52.
   PubMed Web of Science ®Google Scholar
• Laukkanen MO, Mannermaa S, Hiltunen MO, et al. Local hypomethylation in atherosclerosis found in rabbit ec-sod gene. Arterioscler Thromb Vasc Biol. 1999;19(9):2171–2178.
   PubMed Web of Science ®Google Scholar
• Teoh-Fitzgerald ML, Fitzgerald MP, Jensen TJ, et al. Genetic and epigenetic inactivation of extracellular superoxide dismutase promotes an invasive phenotype in human lung cancer by disrupting ECM homeostasis. Mol Cancer Res. 2012;10(1):40–51.
   PubMed Web of Science ®Google Scholar
• Curtis C, Shah SP, Chin S-F, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346–352.
   PubMed Web of Science ®Google Scholar
• Glück S, Ross JS, Royce M, et al. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab. Breast Cancer Res Treat. 2012;132(3):781–791.
   PubMed Web of Science ®Google Scholar
• Sharma P, Bhunia S, Poojary SS, et al. Global methylation profiling to identify epigenetic signature of gallbladder cancer and gallstone disease. Tumour Biol. 2016;37(11):14687–14699.
   PubMedGoogle Scholar
• Divyya S, Naushad SM, Murthy PVLN, et al. GCPII modulates oxidative stress and prostate cancer susceptibility through changes in methylation of RASSF1, BNIP3, GSTP1 and Ec-SOD. Mol Biol Rep. 2013;40(10):5541–5550.
   PubMed Web of Science ®Google Scholar
• Chiba T, Yokosuka O, Fukai K, et al. Cell growth inhibition and gene expression induced by the histone deacetylase inhibitor, trichostatin A, on human hepatoma cells. Oncology. 2004;66(6):481–491.
   PubMed Web of Science ®Google Scholar
• Lakshmi SV, Naushad SM, Reddy CA, et al. Oxidative stress in coronary artery disease: epigenetic perspective. Mol Cell Biochem. 2013;374(1–2):203–211.
   PubMed Web of Science ®Google Scholar
• Kamiya T, Machiura M, Makino J, et al. Epigenetic regulation of extracellular-superoxide dismutase in human monocytes. Free Radic Biol Med. 2013;61:197–205.
   PubMed Web of Science ®Google Scholar
• Zelko IN, Stepp MW, Vorst AL, et al. Histone acetylation regulates the cell-specific and interferon-gamma-inducible expression of extracellular superoxide dismutase in human pulmonary arteries. Am J Respir Cell Mol Biol. 2011;45(5):953–961.
   PubMed Web of Science ®Google Scholar
• Zelko IN, Mueller MR, Folz RJ. CpG methylation attenuates Sp1 and Sp3 binding to the human extracellular superoxide dismutase promoter and regulates its cell-specific expression. Free Radic Biol Med. 2010;48(7):895–904.
   PubMed Web of Science ®Google Scholar
• Chaiswing L, Zhong W, Oberley TD. Increasing discordant antioxidant protein levels and enzymatic activities contribute to increasing redox imbalance observed during human prostate cancer progression. Free Radic Biol Med. 2014;67:342–352.
   PubMed Web of Science ®Google Scholar
• Hashmi AA, Aijaz S, Khan SM, et al. Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients. World J Surg Oncol. 2018;16(1):1.
   PubMedGoogle Scholar
• Li Z-H, Hu P-H, Tu J-H, et al. Luminal B breast cancer: patterns of recurrence and clinical outcome. Oncotarget. 2016;7(40):65024–65033.
   PubMedGoogle Scholar
• Stefansson OA, Moran S, Gomez A, et al. A DNA methylation-based definition of biologically distinct breast cancer subtypes. Mol Oncol. 2015;9(3):555–568.
   PubMed Web of Science ®Google Scholar
• Griess B, Tom E, Domann F, et al. Extracellular superoxide dismutase and its role in cancer. Free Radic Biol Med. 2017;112:464–479.
   PubMed Web of Science ®Google Scholar
• Singh RK, Indra D, Mitra S, et al. Deletions in chromosome 4 differentially associated with the development of cervical cancer: evidence of slit2 as a candidate tumor suppressor gene. Hum Genet. 2007;122(1):71–81.
   PubMed Web of Science ®Google Scholar
• Beder LB, Gunduz M, Ouchida M, et al. Genome-wide analyses on loss of heterozygosity in head and neck squamous cell carcinomas. Lab Invest. 2003;83(1):99–105.
   PubMed Web of Science ®Google Scholar
• Dallol A, Da Silva NF, Viacava P, et al. SLIT2, a human homologue of the drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers. Cancer Res. 2002;62(20):5874–5880.
   PubMed Web of Science ®Google Scholar
• Kim G-J, Cho S-J, Won N-H, et al. Genomic imbalances in Korean hepatocellular carcinoma. Cancer Genet Cytogenet. 2003;142(2):129–133.
   PubMedGoogle Scholar
• Pershouse MA, El-Naggar AK, Hurr K, et al. Deletion mapping of chromosome 4 in head and neck squamous cell carcinoma. Oncogene. 1997;14(3):369–373.
   PubMed Web of Science ®Google Scholar
• Polascik TJ, Cairns P, Chang WY, et al. Distinct regions of allelic loss on chromosome 4 in human primary bladder carcinoma. Cancer Res. 1995;55(22):5396–5399.
   PubMed Web of Science ®Google Scholar
• Sherwood JB, Shivapurkar N, Lin WM, et al. Chromosome 4 deletions are frequent in invasive cervical cancer and differ between histologic variants. Gynecol Oncol. 2000;79(1):90–96.
   PubMed Web of Science ®Google Scholar
• Shivapurkar N, Maitra A, Milchgrub S, et al. Deletions of chromosome 4 occur early during the pathogenesis of colorectal carcinoma. Hum Pathol. 2001;32(2):169–177.
   PubMed Web of Science ®Google Scholar
• Shivapurkar N, Sood S, Wistuba II, et al. Multiple regions of chromosome 4 demonstrating allelic losses in breast carcinomas. Cancer Res. 1999;59(15):3576–3580.
   PubMed Web of Science ®Google Scholar
• Shivapurkar N, Virmani AK, Wistuba II, et al. Deletions of chromosome 4 at multiple sites are frequent in malignant mesothelioma and small cell lung carcinoma. Clin Cancer Res. 1999;5(1):17–23.
   PubMed Web of Science ®Google Scholar
• Kwei KA, Kung Y, Salari K, et al. Genomic instability in breast cancer: pathogenesis and clinical implications. Mol Oncol. 2010;4(3):255–266.
   PubMed Web of Science ®Google Scholar